Veru Inc. — Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2023; comparisons are with fiscal 2022. Although the request references 2023 Q4, this filing is an annual report and does not provide a clear standalone Q4 results summary. Unless noted, financial amounts are in U.S. dollars.
Business context
Veru is a late-clinical-stage biopharmaceutical company with the marketed FC2 female condom and drug candidates enobosarm and sabizabulin. FC2 generated nearly all revenue. The company sold substantially all ENTADFI assets in April 2023. Management prioritized enobosarm development, particularly a proposed obesity study, and said further sabizabulin development depends on external funding.
Key financial metrics
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net revenue | $16.3 million | $39.4 million |
| Gross profit / margin | $7.6 million / 46% | $30.6 million / 78% |
| Operating loss | $93.7 million | $83.2 million |
| Net loss | $93.1 million; $1.10 per share | $83.8 million; $1.05 per share |
| Operating cash flow | $(88.0) million | $(47.5) million |
| Cash and cash equivalents at year-end | $9.6 million | $80.2 million |
| Working capital at year-end | $3.2 million | $63.3 million |
FY2023 R&D expense was $51.1 million, down from $70.6 million; SG&A was $48.1 million, up from $43.2 million. Total assets were $50.6 million and stockholders’ equity was $17.8 million at year-end. Cash from investing activities was $6.3 million, including $7.0 million received for ENTADFI assets; financing activities provided $11.1 million, mainly from equity sales.
The filing reports no remaining term-loan obligations under the former SWK credit agreement, repaid in 2021. A residual royalty obligation remained at $9.7 million, including an embedded derivative, and requires payments equal to 5% of FC2 product revenue. Operating lease liabilities totaled $4.7 million.
Material changes versus FY2022
- Revenue fell 59%. U.S. prescription-channel FC2 revenue declined to $5.8 million from $30.2 million; global public-health-sector revenue rose to $10.5 million from $9.1 million. The shift toward lower-margin public-sector sales and reduced production volume contributed to the gross-margin decline.
- The Pill Club, which generated 24% of FY2023 revenue, filed for bankruptcy; Veru recorded a $3.9 million credit-loss provision and expects no future revenue from it. A further major prescription-channel customer generated $11.4 million in FY2022 and none in FY2023.
- Operating cash use increased to $88.0 million from $47.5 million, while year-end cash declined by $70.6 million. Management said available cash was insufficient for its operating, investing, and financing needs for the 12 months after the financial statements’ issuance.
- R&D spending declined as the company refocused development; SG&A rose, including higher share-based compensation and costs related to potential sabizabulin commercialization. Veru also recorded a $3.9 million impairment for abandoned development assets and a $5.7 million gain on the ENTADFI asset sale.
Outlook, risks, contingencies, and unusual items
- Going concern: The auditor’s report includes an explanatory paragraph citing substantial doubt about Veru’s ability to continue as a going concern for at least 12 months after issuance. The company expects to seek equity, debt, or other financing; availability and terms are uncertain and equity financing could dilute shareholders.
- Development plans: Subject to regulatory clearance and funding, Veru planned a Phase 2b enobosarm study with a GLP-1 receptor agonist, with first data expected in the second half of 2024. Breast-cancer Phase 3 Stage 1b work was paused pending sufficient funding; topline data were projected for early 2025 if funded. Sabizabulin’s COVID-19 EUA request was declined in February 2023; a Phase 3 viral-ARDS trial requires external funding. Veru was not selected for a planned BARDA-sponsored Phase 2 ARDS trial.
- ENTADFI proceeds: The $20 million stated purchase price includes future installments, and up to $80 million in sales-based milestone payments. Veru recognized only $7 million of nonrefundable consideration received by year-end and cautioned that future payments and the value or liquidity of BWV preferred shares are uncertain.
- Contingencies: A supplier claims approximately $10 million for sabizabulin-related products and services; Veru disputes the claim but reserved the full amount. Securities and derivative stockholder lawsuits related primarily to sabizabulin statements are pending; potential losses were not estimable. The filing also identifies possible investigation risk relating to The Pill Club’s business practices.
- Reporting controls: Veru restated its previously issued June 2023 quarterly financial information and reported a material weakness in controls over accounting for complex, nonrecurring transactions. Management said remediation was underway; disclosure controls and internal control over financial reporting were ineffective as of September 30, 2023.
- FC2 operating risks: Manufacturing is concentrated at one Malaysian facility. A key nitrile supplier plans to close the facility producing FC2’s specialty-grade material; transition work and FDA approval of an alternative grade may be required. The company also cites customer concentration, public-sector tender volatility, pricing pressure, competition, and raw-material availability.
Important facts for investors to verify
- Current cash, cash runway, financing completed since the December 8, 2023 filing date, and the company’s ability to fund planned trials.
- Actual FC2 revenue trends by channel, customer concentration, and whether the company’s direct-to-patient portal and replacement distribution relationships can offset lost telehealth sales.
- Collection of remaining ENTADFI installments, any milestone payments, and the realizable value of BWV preferred shares.
- Status, cost, funding, regulatory clearance, enrollment, and results of the enobosarm and sabizabulin clinical programs.
- Resolution and cash impact of the supplier dispute and shareholder litigation; progress in remediating the material weakness and avoiding further restatements.
- Continuity of FC2 raw-material supply and any required regulatory approval for the material transition.